证券代码：300119 证券简称：瑞普生物 公告编号：2024-058 天津瑞普生物技术股份有限公司 第五届监事会第十五次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 1、审议通过了《关于收购中瑞华普科技有限公司部分股权暨关联交易的议 案》 经审议，监事会认为：公司此次收购中瑞华普科技有限公司 15%股权事项， 决策程序符合有关法律法规和《公司章程》的规定，交易行为符合公司利益，本 次股权转让定价公允、合理，不存在损害公司及股东利益的情形，对公司持续经 营和资产状况无不良影响。 具体内容详见公司在深圳证券交易所网站（http://www.szse.cn）及巨潮资讯 网（http://www.cninfo.com.cn）披露的《关于收购中瑞华普科技有限公司部分股 权暨关联交易的公告》。 表决结果：同意 2 票，反对 0 票，弃权 0 票，关联监事周仲华回避表决。 三、备查文件 1、经与会监事签字并加盖公司印章的监事会决议。 特此公告。 天津瑞普生物技术股份有限公司（以下简称"公司"）第五届监事会第十五次 （临时）会 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-059 天津瑞普生物技术股份有限公司 关于收购中瑞华普科技有限公司部分股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： （一）交易内容 为持续完善公司在宠物大健康航道的战略布局，深化公司与瑞派宠物医院及 旗下中瑞供应链平台价值链管理，加强双方在宠物医疗渠道推广、品牌建设上的 深度战略协同，公司于 2024 年 11 月 7 日在天津市签署《股权转让协议》，拟以 自有资金或自筹资金 13,138.43 万元收购李守军、梁武、苏雅拉达来、李旭东、 鲍海丽、周仲华持有的中瑞华普合计 15%股权（以下简称"本次交易"）。 中瑞华普核心资产为瑞派宠物医院管理股份有限公司（简称"瑞派宠物医院"） 17.5179%股权，根据银信资产评估有限公司 2024 年 3 月 25 日出具的《天津瑞普 生物技术股份有限公司拟对其他非流动金融资产进行公允价值计量涉及的瑞派 宠物医院管理股份有限公司等 4 家公司的股东部分权益价值项目咨询报告》（银 信咨报字(2024)第 A0003 号），截 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-057 天津瑞普生物技术股份有限公司 第五届董事会第十九次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 天津瑞普生物技术股份有限公司（以下简称"公司"）第五届董事会第十九次 （临时）会议于 2024 年 11 月 7 日在公司会议室以现场结合通讯表决方式召开。 会议通知于 2024 年 11 月 5 日以书面及网络方式送达全体董事。公司应出席董事 9 人，实际出席董事 9 人（其中董事杨鶄，独立董事郭春林、才学鹏、周睿以通 讯方式参会），参与表决董事 9 人。本次会议由董事长李守军先生主持，公司高 级管理人员列席了会议。本次会议的召集、召开和表决程序符合《公司法》《证 券法》等法律法规和《公司章程》的规定。 具体内容详见公司在深圳证券交易所网站（http://www.szse.cn）及巨潮资讯 网（http://www.cninfo.com.cn）披露的《关于收购中瑞华普科技有限公司部分股 权暨关联交易的公告》。 表决结果：同意 7 票，反对 0 票 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 21.50 CNY over the next six months [1][3][11]. Core Insights - The company reported a stable revenue growth of 10.06% year-on-year for the first three quarters of 2024, achieving a revenue of 1.747 billion CNY. However, the net profit attributable to the parent company decreased by 10.58% year-on-year to 245 million CNY, indicating challenges such as increased market competition and rising costs [1][2]. - The company is actively exploring new markets, particularly in the pet healthcare sector, which has shown significant growth potential. The launch of the cat trivalent vaccine has been successful, with sales exceeding one million doses [2][3]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 648 million CNY, a year-on-year increase of 9.22%, while the net profit attributable to the parent company was 86 million CNY, down 10.3% year-on-year [1]. - The company’s revenue for 2024 is projected to reach approximately 2.249 billion CNY, with a growth rate of 10.70% expected in 2025 [4][8]. Research and Development - The company has increased its R&D investment, with R&D expenses reaching 51.68 million CNY in Q3 2024, representing a rate of 7.98% of revenue. This investment supports the development of new products, including vaccines and enzyme preparations [2][3]. Market Position and Strategy - The company has established a strong market presence in the animal healthcare industry and is expanding its pet product offerings. The integration of various sales channels, including partnerships with pet hospitals, is expected to enhance sales growth [2][3]. - The pet healthcare segment is identified as a blue ocean market with significant growth potential, supported by the successful launch of new products and an expanding distribution network [2][3]. Earnings Forecast - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 0.70 CNY, 0.86 CNY, and 1.05 CNY, respectively, with corresponding dynamic price-to-earnings (PE) ratios of 24, 20, and 16 [3][4][11].

证券代码：300119 证券简称：瑞普生物 公告编号：2024-055 关于回购股份事项前十名股东及前十名无限售条件股东 天津瑞普生物技术股份有限公司 持股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2024 年 11 月 1 日召 开第五届董事会第十八次（临时）会议，审议通过了《关于回购公司股份方案的 议案》。公司拟使用商业银行股票回购专项贷款及自有资金以集中竞价交易方式 回购公司发行的无限售条件的 A 股流通股，用于后续实施股权激励或员工持股 计划，具体内容详见公司于 2024 年 11 月 4 日在深圳证券交易所网站 （http://www.szse.cn）及巨潮资讯网（http://www.cninfo.com.cn）披露的《关于回 购公司股份方案暨与金融机构签订股票回购借款合同的公告》（公告编号：2024- 054）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，现将董事会公告回购股份决议的前一个交易日 （即 2024 年 11 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-056 1、天津瑞普生物技术股份有限公司（以下简称"公司"）拟使用商业银行股 票回购专项贷款及自有资金以集中竞价交易方式回购公司无限售条件的A股流 通股（以下简称"本次回购"），用于股权激励或员工持股计划。本次回购资金总 额不低于人民币10,000.00万元、不超过人民币16,000.00万元，回购股份的价格不 超过人民币19.50元/股。按照本次回购金额上限不超过人民币16,000.00万元，回 购价格上限不超过人民币19.50元/股进行测算，回购数量约为820.51万股，回购股 份比例约占公司总股本的1.76%。按照本次回购金额下限不低于人民币10,000.00 万元，回购价格上限不超过人民币19.50元/股进行测算，回购数量约为512.82万 股，回购股份比例约占公司总股本的1.10%，具体回购股份的数量以回购结束时 实际回购的股份数量为准。本次回购股份的实施期限为自公司董事会审议通过本 回购股份方案之日起不超过6个月。 2、本次回购股份方案已经公司于2024年11月1日召开的第五届董事会第十八 次（临时）会议审议通过。具体内容详见公司在深 ...

Company Overview - The company, Ruipu Biology, is the first A-share listed company in China focusing on the veterinary medicine field [1] - It adheres to the corporate values of "customer-centric,奋斗者为本,敢为人先,使命必达" [1] - The company focuses on cutting-edge developments in biopharmaceuticals such as genetic engineering vaccines, suspension culture processes, new crystal drugs, and AI drug research [1] - It provides comprehensive disease prevention and health solutions for economic and companion animals throughout their life cycles [1] Business Operations - Ruipu Biology has over 20 subsidiary companies spread across 8 provinces and cities including Tianjin, Hubei, and Hunan [1] - The company operates 11 production bases that have passed the new version of veterinary drug GMP acceptance and 1 large-scale feed additive production base [1] - It offers more than 500 animal products for livestock, poultry, and pets [1] - The company is an integrated animal health product manufacturer and service provider, covering biological products, drug raw materials, drug preparations, and feed additives [1] Industry Recognition - Ruipu Biology was recognized in the "China Listed Companies New Quality Productivity 50强" list, reflecting its strong development momentum and market recognition of its new quality productivity [1] - New quality productivity represents new technologies, value creation, adaptation to new industries, and reshaping of new momentum [1] Future Outlook - The company aims to place technological innovation at the core of its development, continuously deepen technological innovation and product iteration, and accelerate its growth [2] - Ruipu Biology aspires to become a leading enterprise in the global animal health industry, contributing to the prosperity of China's animal husbandry, animal health, and human well-being [2]

Core Insights - The "High-Yield Calcidiol Cell Factory Synthesis" application scenario has broken through traditional production bottlenecks, offering advantages such as shorter production cycles, lower costs, reduced energy consumption, and no pollution (no heavy metal catalysts required) compared to traditional chemical synthesis and biological fermentation methods [1] - This green bio-manufacturing method integrates industrial and innovative resources from Ruipu Biology and the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, forming a service platform capable of providing process amplification and rapid product development for calcidiol and other raw material production companies [1] - The project is expected to set a benchmark in Tianjin and nationwide, driving the transformation of bio-manufacturing processes and green manufacturing upgrades in the Binhai New Area and across the country, significantly promoting the development of a bio-manufacturing industrial cluster in the Binhai New Area [1] Industry Impact - The application of this scenario will lead to a shift in the bio-manufacturing industry towards more sustainable and efficient production methods, reducing reliance on high-cost, high-energy, and high-pollution practices [1] - The collaboration between Ruipu Biology and the Tianjin Institute of Industrial Biotechnology highlights the importance of integrating industrial and academic resources to drive innovation in the bio-manufacturing sector [1] Regional Development - The project is poised to have a significant impact on the Binhai New Area, fostering the growth of a bio-manufacturing industrial cluster and setting a model for other regions to follow [1] - The widespread adoption of this technology could lead to a nationwide transformation in bio-manufacturing practices, enhancing the competitiveness of the industry in China [1]

Investment Rating - Investment rating: Buy (maintained) [1] Core Views - The company achieved operating revenue of 648 million yuan in Q3 2024, a year-on-year increase of 9.22% [1] - For the first three quarters of 2024, the company reported operating revenue of 1.75 billion yuan, up 10.1% year-on-year, and a net profit attributable to shareholders of 245 million yuan, down 10.6% year-on-year [1] - The poultry segment showed significant growth, with revenue of 1.2 billion yuan in the first three quarters of 2024, a 19% increase year-on-year, driven by strengthened cooperation with major clients and market share gains in high-pathogenic avian influenza vaccines [1] - The livestock segment's revenue improved by over 20% quarter-on-quarter in Q3 2024, supported by a recovery in the breeding industry [1] - The pet segment has expanded, with nearly 100 core distributors and over 6,000 stores nationwide since the launch of the cat trivalent vaccine in January [1] Financial Performance Summary - Q3 2024 gross profit margin was 49.39%, a decrease of 1.56 percentage points year-on-year, while net profit margin was 15.12%, down 3.46 percentage points year-on-year [1] - The gross margin for the first three quarters of 2024 showed a continuous improvement trend, with figures of 47.7%, 49.3%, and 50.9% respectively [1] - The company expects operating revenue to reach 2.71 billion yuan, 3.12 billion yuan, and 3.51 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 20.4%, 15.0%, and 12.5% [2][3]

证券代码：300119 证券简称：瑞普生物 公告编号：2024-054 天津瑞普生物技术股份有限公司 关于回购公司股份方案 暨与金融机构签订股票回购借款合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 6、回购期限：回购股份的实施期限为自董事会审议通过回购股份方案之日 起 6 个月内。 7、回购股份的数量占公司总股本的比例： 按照本次回购金额上限不超过人民币 16,000.00 万元，回购价格上限不超过 人民币 19.50 元/股进行测算，回购数量约为 820.51 万股，回购股份比例约占公 司总股本的 1.76%。按照本次回购金额下限不低于人民币 10,000.00 万元，回购 价格上限不超过人民币 19.50 元/股进行测算，回购数量约为 512.82 万股，回购 股份比例约占公司总股本的 1.10%。 8、相关股东是否存在减持计划： 1 天津瑞普生物技术股份有限公司（以下简称"公司"）拟以集中竞价交易方 式回购公司股份，主要内容如下： 1、回购股份的种类：无限售条件的 A 股流通股。 2、回购股份的用途：用于股权激励或员工持股计 ...